J

    Jade Biosciences, Inc. (JBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $21.36
    +0.52 (+2.50%)

    Market Cap: $1.36B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    5%(1/21)
    Avg Surprise
    -1654.71%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.54
    Range$-0.54 - $-0.54
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$0.00+100.0%
    7d ago$0.00+100.0%
    Current$-0.54
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.37
    Range$-1.37 - $-1.37
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.37---
    Sep 26EST
    		-$-0.54---
    Jun 26
    Reported Aug 10
    		$-0.76$-0.66-15.15%Miss+11.6%
    Mar 26
    Reported May 7
    		$-0.57$-0.48-18.75%Miss+95.3%
    Dec 25
    Reported Mar 6
    		$N/A$-0.47N/ABeat-
    Sep 25
    Reported Nov 13
    		$-0.48$-0.67+28.36%Beat+97.6%
    Jun 25
    Reported Aug 13
    		$-0.86$-0.48-79.17%Miss+97.1%
    Mar 25
    Reported Apr 25
    		$-12.10$-2.05-490.24%Miss-1357.8%
    Dec 24
    Reported Mar 27
    		$-6.61$-0.40-1542.24%Miss+74.5%
    Sep 24
    Reported Nov 11
    		$-19.60$-0.58-3274.66%Miss-2660.6%
    Jun 24
    Reported Aug 12
    		$-30.10$-0.85-3441.18%Miss-3860.5%
    Mar 24
    Reported May 13
    		$-0.83$-0.76-9.21%Miss-23.9%
    Dec 23
    Reported Mar 25
    		$-25.90$-0.74-3400.00%Miss-21.3%
    Sep 23
    Reported Nov 13
    		$-0.71$-0.69-2.90%Miss-26.8%
    Jun 23
    Reported Aug 14
    		$-0.76$-0.70-8.57%Miss+95.6%
    Mar 23
    Reported May 16
    		$-0.67$-0.57-17.54%Miss+95.7%
    Dec 22
    Reported Mar 29
    		$-21.35$-0.61-3400.00%Miss-79.4%
    Sep 22
    Reported Nov 14
    		$-0.56$-0.50-12.00%Miss+93.8%
    Jun 22
    Reported Aug 17
    		$-17.15$-0.49-3400.00%Miss+97.9%
    Mar 22
    Reported May 16
    		$-15.75$-0.45-3400.00%Miss-23.3%
    Dec 21
    Reported Mar 30
    		$-11.90$-0.33-3506.06%Miss-
    Sep 21
    Reported Nov 15
    		$-9.10$-0.26-3400.00%Miss-
    Jun 21
    Reported Aug 16
    		$-833.00$-23.80-3400.00%Miss-
    Mar 21
    Reported May 6
    		$-12.77$-0.62-1959.68%Miss-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00

    Key Metrics

    Valuation
    P/E Ratio-8.00EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-89.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio14.93xQuick Ratio14.93x
    Trading Statistics
    BetaN/AAvg Volume782.01K
    52-Week High$28.0052-Week Low$6.91

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$21.67
    SMA 20$22.16
    SMA 50$21.42
    SMA 200$17.82
    EMA 10$21.59
    EMA 20$21.66
    EMA 50$21.22
    EMA 200$20.06

    MACD

    Line: 0.06Signal: 0.29Hist: -0.23

    ADX

    ADX: 13.9+DI: 17.2-DI: 19.4

    Aroon & PSAR

    Aroon Up56.0
    Aroon Down4.0
    PSAR$24.01

    Bollinger Bands

    Upper Band$24.28
    Lower Band$20.04
    %B Position1914%(Upper)
    Band Width0.31

    RSI (14-Day)

    Neutral
    48.5

    Momentum Oscillators

    Stoch %K16.9
    Stoch %D19.0
    Williams %R-78.3
    ROC (10d)-8.9%
    Momentum-2.09
    CCI (20d)-93.0
    MFI (14d)47.7

    Volatility Measures

    ATR (14d)$1.35(6.3%)
    StdDev (20d)1.06
    Hist Vol61.0%(High)

    Volume Flow

    VWAP$21.05
    OBV617.9K
    AD Line16.8B
    CMF (20d)0.119

    Volume Metrics

    Avg Vol (20d)788.6K
    Vol Ratio1.1x
    VWMA (20d)$22.33

    Pivot Points

    R3$21.81
    R2$21.61
    R1$21.22
    Pivot Point$21.02
    S1$20.63
    S2$20.43
    S3$20.04

    Advanced Oscillators

    TSI1.68
    Ultimate Osc44.8
    KST48.74

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0N/A$0
    Cost of Revenue$0$0$9,000$0$0$0$8,000$0$0$0$28,000$0
    Gross Profit$0$0$-9,000$0$0$0$-8,000$0$0$0$-28,000$0
    Operating Expenses$58.92M$43.45M$54.98M$27.40M$27.78M$23.38M$6.40M$15.55M$26.16M$24.62M$22.07M$21.37M
    R&D$50.06M$36.05M$48.56M$22.01M$22.55M$20.02M$1.53M$13.66M$21.25M$20.08M$17.81M$16.88M
    SG&A$8.85M$7.39M$6.41M$5.39M$5.23M$3.36M$4.87M$1.90M$4.92M$4.54M$4.25M$4.48M
    Operating Income$-58,916,000$-43,445,000$-54,976,000$-27,401,000$-27,778,000$-23,384,000$-6,403,000$-15,555,000$-26,165,000$-24,618,000$-22,066,000$-21,368,000
    Interest Income$3.23M$3.10M$2.83M$2.25M$1.83M$615,000$1.03M$388,000$1.40M$1.44M$1.71M$1.80M
    Interest Expense$0$0$12.61M$0$4.36M$14.79M$0$1.31M$0$0$0$0
    Income Before Tax$-55,750,000$-40,352,000$-67,588,000$-25,112,000$-32,134,000$-38,169,000$-5,375,000$-16,867,000$-24,775,000$-23,186,000$-20,357,000$-19,563,000
    Income Tax Expense$15,000$16,000$0$0$0$0$0$0$0$0$0$0
    Net Income$-55,765,000$-40,368,000$-67,583,000$-25,175,000$-32,134,000$-38,169,000$-5,430,000$-16,867,000$-24,775,000$-23,186,000$-20,413,000$-19,563,000
    EBITDA$-59,327,000$-43,929,000$-55,577,000$-27,354,000$-33,957,000$-38,784,000$-6,731,000$-16,908,000$-26,835,000$-25,349,000$-22,977,000$-22,150,000
    EBIT$-58,978,000$-43,445,000$-54,976,000$-27,366,000$-33,962,000$-38,784,000$-6,403,000$-16,665,000$-26,171,000$-24,618,000$-22,066,000$-21,367,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about JBIO

    News

    Jade Biosciences advances JADE101 for IgAN with promising Phase 1 results and Phase 2 data due in 2027

    Jade Biosciences is progressing JADE101, a selective APRIL inhibitor for IgA nephropathy (IgAN), with encouraging Phase 1 results showing a significant reduction in IgA levels and a good safety profile. The company aims for quarterly dosing to improve patient adherence compared to competitors. Key interim results from the Phase 2 JUNIPER trial are anticipated in 2027.

    Pluang•8/19/26•
    Bullish

    Jade Biosciences Company Profile & Introduction

    This document is intended to be a company profile and introduction for Jade Biosciences. The content is currently empty, suggesting it will provide foundational information about the company.

    Moomoo•8/18/26•
    Neutral

    Jade Biosciences (JBIO) Stock Analysis Report | Financials & Insights

    This report provides a financial analysis of Jade Biosciences (JBIO), a clinical-stage biotechnology company. It covers stock performance, future growth potential based on analyst ratings, and past performance metrics like the Sharpe ratio. The company is focused on developing therapies for autoimmune diseases with its flagship candidate, JADE101, currently in Phase 1 clinical trials.

    Benzinga España•8/18/26•
    Neutral

    Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On?

    Jade Biosciences (JBIO) recently released its Q2 2026 results, reporting a net loss of $55.77 million. Despite strong year-to-date share price returns of 63.91% and a 1-year total shareholder return of 216.64%, the stock's 90-day return declined, and it trades well below the average analyst target. The company remains unprofitable, with a Price-to-Book ratio of 3.4x, which is considered overvalued compared to industry peers.

    Sahm•8/14/26•
    Somewhat-Bearish

    H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $55

    H.C. Wainwright has reiterated its Buy rating for Jade Biosciences (JBIO.US), keeping the target price at $55. This indicates continued confidence in the company's performance and future prospects from the analyst firm.

    Moomoo•8/14/26•
    Bullish

    Frequently Asked Questions About JBIO

    Does JBIO pay dividends?
    Jade Biosciences, Inc. (JBIO) has a dividend payment track record. See the JBIO dividend history page for its current payment status, yield, and streaks.
    What is JBIO's market cap?
    Jade Biosciences, Inc. (JBIO) has a market capitalization of $1.36B with a current stock price of $21.36.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In